Table of Content




1. Executive Summary


2. Global Hemophilia Treatment Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges 


3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Hemophilia Treatment Market Trends (2018-2023) and Forecast (2024-2030)

3.3: Global Hemophilia Treatment Market by Type
3.3.1: Hemophilia A
3.3.2: Hemophilia B

3.4: Global Hemophilia Treatment Market by Drug Therapy
3.4.1: Recombinant Coagulation Factor Concentrates Therapy
3.4.2: Plasma Derived Coagulation Factor Concentrates Therapy
3.4.3: Non-Factor Replacement Therapy

3.5: Global Hemophilia Treatment Market by End Use
3.5.1: Hospitals
3.5.2: Clinics
3.5.3: others




4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Hemophilia Treatment Market by Region
4.2: North American Hemophilia Treatment Market
4.2.2: North American Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy


4.3: European Hemophilia Treatment Market
4.3.1: European Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
4.3.2: European Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy


4.4: APAC Hemophilia Treatment Market
4.4.1: APAC Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
4.4.2: APAC Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy


4.5: ROW Hemophilia Treatment Market
4.5.1: ROW Hemophilia Treatment Market by Type: Hemophilia A and Hemophilia B
4.5.2: ROW Hemophilia Treatment Market by Drug Therapy: Recombinant Coagulation Factor Concentrates Therapy, Plasma Derived Coagulation Factor Concentrates Therapy, and Non-Factor Replacement Therapy



5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis


6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Hemophilia Treatment Market by Type
6.1.2: Growth Opportunities for the Global Hemophilia Treatment Market by Drug Therapy
6.1.3: Growth Opportunities for the Global Hemophilia Treatment Market by End Use
6.1.4: Growth Opportunities for the Global Hemophilia Treatment Market by Region

6.2: Emerging Trends in the Global Hemophilia Treatment Market

6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Hemophilia Treatment Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hemophilia Treatment Market
6.3.4: Certification and Licensing


7. Company Profiles of Leading Players
7.1: Baxter
7.2: Octapharma
7.3: CSL Limited
7.4: Grifols
7.5: Bayer
7.6: Pfizer
7.7: Sanofi
7.8: Ferring
7.9: BioMarin
7.10: Sangamo Therapeutics